Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia

Blood (2020) 135 (17): 1472–1483.

https://doi.org/10.1182/blood.2019003538

Published: 2020

Includes: Supplemental data

Journal Articles

Role of HDAC8 Upregulation in Resistance of FLT3-ITD AML Stem Cells to FLT3 Inhibitors

Jun Long, Mingyuan Jia, Weiyue Fang, Xinjie Chen, Zhongyu Wang, Lili Mu, Rufang Xiang, Jun-Min LI, MD PhD, Dengli Hong, PhD, Aibin Liang, MD PhD, Jiong Hu, MD

Blood (2019) 134 (Supplement_1): 1268.

https://doi.org/10.1182/blood-2019-128394

Published: 2019

Journal Articles

Dynamic Analysis of Cytokine Profile for Cytokine Release Syndrome in Multiple Myeloma Patients after CAR-T Cell Therapy

Shuangshuang Yang, MD, Lijuan Chen, MD PhD, Jie Xu, MD PhD, Frank Xiao-Hu Fan, MD PhD, Sun Yan, PhD, Wen Wu, MD PhD, Yan Wang, MD, Jin Wang, MD PhD, Shiwei Jin, MD, Yuebo Zhou, Yuanfang Liu, MD PhD, Yan Zhuang, PhD, Wu Zhang, PhD, Jun-Min Li, Jian Hou, PhD MD, Jian-Yong Li, MD PhD, Zhu Chen, PhD, Jian-Qing Mi, MD PhD, Sai-Juan Chen, PhD

Blood (2019) 134 (Supplement_1): 5617.

https://doi.org/10.1182/blood-2019-131799

Published: 2019

Journal Articles

Identification of Individualized Minimal Residual Disease in Acute Myeloid Leukemia By Flow Cytometry and Its Application of Prognostic Significance

Jing-Ni Sui, Qiu-Sheng Chen, Yun-Xiang Zhang, Yan Sheng, Jing Wu, Jun-Min Li, Jiong Hu, MD, Xiang-Qin Weng, Bing Chen, MD PhD

Blood (2018) 132 (Supplement 1): 1522.

https://doi.org/10.1182/blood-2018-99-112367

Published: 2018

Journal Articles

Mutation Profiling and Associated Clinical Features in Chinese Cytogenetically Normal Acute Myeloid Leukemia Patients

Shu Wang, Yun-Xiang Zhang, Ting Huang, Kankan Wang, PhD, Jun-Min LI, MD PhD, Jin-yan Huang, PhD, Bing Chen, MD PhD

Blood (2017) 130 (Supplement 1): 5102.

https://doi.org/10.1182/blood.V130.Suppl_1.5102.5102

Published: 2017

Journal Articles

Genome-Wide Abnormality Patterns of B-Lineage Acute Lymphoblastic Leukemia in Adults in Comparison with Pediatric Cases

Blood (2014) 124 (21): 3786.

https://doi.org/10.1182/blood.V124.21.3786.3786

Published: 2014

Journal Articles

A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value

Blood (2014) 124 (10): 1645–1654.

https://doi.org/10.1182/blood-2014-02-554204

Published: 2014

Includes: Supplemental data

Journal Articles

Serum 2-Hydroxyglutarate Level Is a Prognostic Marker in Acute Myeloid Leukemia

Blood (2012) 120 (21): 1433.

https://doi.org/10.1182/blood.V120.21.1433.1433

Published: 2012

Journal Articles

Long-Term Outcome of Imatinib Treatment in Chronic Myeloid Leukemia (CML) Patients in Shanghai: An International Patient Assistance Programs (GIPAP) Analysis.

Ai-hua Wang, Li Zhou, Yu Zheng, Jun-min Li, Zhi-Xiang Shen, MD, Jiong Hu, MD

Blood (2009) 114 (22): 4275.

https://doi.org/10.1182/blood.V114.22.4275.4275

Published: 2009

Journal Articles

Cytogenetic and Molecular Features of 1331 Chinese Patients with Primary Acute Lymphoblastic Leukemia (ALL).

Blood (2009) 114 (22): 4718.

https://doi.org/10.1182/blood.V114.22.4718.4718

Published: 2009

Journal Articles

Activation of PI3K/Akt/mTOR Pathway in Diffuse Large B-Cell Lymphomas: Clinical Significance and Inhibitory Effect by Rituximab.

Jun-min Li, Zi-zhen Xu, Ai-hua Wang, Jiong Hu, MD

Blood (2009) 114 (22): 1934.

https://doi.org/10.1182/blood.V114.22.1934.1934

Published: 2009

Journal Articles

Front-Line Therapy with Arsenic Trioxide/All- Trans -Retinoic Acid Combination and Chemotherapy Improves Cure Rates in Newly Diagnosed Patients with Acute Promyelocytic Leukemia

Jiong Hu, MD, Yuan-fang Liu, Chuan-feng Wu, Guang-biao Zhou, Zhi-Xiang Shen, Jun-min Li, Zhen-Yi Wang, Sai-Juan Chen, Zhu Chen

Blood (2008) 112 (11): 2970.

https://doi.org/10.1182/blood.V112.11.2970.2970

Published: 2008

Journal Articles

PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor

Wei-Li Zhao, Yan-Yan Liu, Qun-Ling Zhang, Li Wang, Christophe Leboeuf, Yi-Wen Zhang, Jie Ma, José-Francisco Garcia, Yong-Ping Song, Jun-Min Li, Zhi-Xiang Shen, Zhu Chen, Anne Janin, Sai-Juan Chen

Blood (2008) 111 (7): 3867–3871.

https://doi.org/10.1182/blood-2007-08-108654

Published: 2008

Journal Articles

Rituximab plus CHOP (R-CHOP) overcomes PRDM1 -associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma

Yan-Yan Liu, Christophe Leboeuf, Jing-Yi Shi, Jun-Min Li, Li Wang, Yang Shen, José-Francisco Garcia, Zhi-Xiang Shen, Zhu Chen, Anne Janin, Sai-Juan Chen, Wei-Li Zhao

Blood (2007) 110 (1): 339–344.

https://doi.org/10.1182/blood-2006-09-049189

Published: 2007

Journal Articles

Long-Term Follow-Up Confirms the Benefit of All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As2O3) as Front Line Therapy for Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Yuan-Fang Liu, Yong-Mei Zhu, Zhan-Zhong Shi, Jun-Min Li, Li Wang, Yu Chen, Zhi-Xiang Shen, Jiong Hu

Blood (2006) 108 (11): 565.

https://doi.org/10.1182/blood.V108.11.565.565

Published: 2006

Journal Articles

Long Term Follow up of the Patients with Non-Hodgkin’s Lymphoma Treated with Rituximab in Combination with CHOP Regimen.

Jun-Min Li

Blood (2005) 106 (11): 4776.

https://doi.org/10.1182/blood.V106.11.4776.4776

Published: 2005

Journal Articles

Study of Sequential Treatment of Newly Diagnosed De Novo AML Patients with DA and CAG Regimens as Remission Induction Therapy.

Hui ping Sun, MD, Wei Hong Liu, MD, Jun min Li, MD, Qiu sheng Chen, MD, Yu Chen, MD

Blood (2005) 106 (11): 4630.

https://doi.org/10.1182/blood.V106.11.4630.4630

Published: 2005

Journal Articles

A 3-Year Follow-Up of All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As 2 O 3 ) as Front Line Therapy for Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Jiong Hu, Yuan-Fang Liu, Yong-Mei Zhu, Zhan-Zhong Shi, Jun-Min Li, Li Wang, Yu Chen, Zhi-Xiang Shen

Blood (2005) 106 (11): 886.

https://doi.org/10.1182/blood.V106.11.886.886

Published: 2005

Journal Articles

Phase I Clinical Trial of Glivec in Combination with Tetra-Arsenic Tetra-Sulfide in the Treatment of CML Patients in Advanced Phase.

Jun-Min Li, Ai-Hua Wang, Hui-Ping Sun, Yang Shen, Rui-Hua Zhao, Bai-Wei Gu, Bing Chen, Wen Xing, Zhi-Xiang Shen, Zhen-Yi Wang, Sai-Juan Chen, Zhu Chen

Blood (2004) 104 (11): 4653.

https://doi.org/10.1182/blood.V104.11.4653.4653

Published: 2004

Journal Articles

Cytogenetic Abnormalities Predict Disease Progression in Primary Myelodysplastic Syndrome: A Multicentric Study in 508 Chinese Patients.

Bing Chen, Wei-Li Zhao, Jie Jin, Yong-Quan Xue, Xin Cheng, Xiao-Ting Chen, Jing Cui, Zhi-Mei Chen, Qi Cao, Guang Yang, Ying Yao, Jian-Hua Tong, Jun-Min Li, Jue Chen, Shu-Min Xiong, Zhi-Xiang Shen, Zhu Chen, Sai-Juan Chen

Blood (2004) 104 (11): 1451.

https://doi.org/10.1182/blood.V104.11.1451.1451

Published: 2004

NARROW

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia

Role of HDAC8 Upregulation in Resistance of FLT3-ITD AML Stem Cells to FLT3 Inhibitors

Dynamic Analysis of Cytokine Profile for Cytokine Release Syndrome in Multiple Myeloma Patients after CAR-T Cell Therapy

Identification of Individualized Minimal Residual Disease in Acute Myeloid Leukemia By Flow Cytometry and Its Application of Prognostic Significance

Mutation Profiling and Associated Clinical Features in Chinese Cytogenetically Normal Acute Myeloid Leukemia Patients

Genome-Wide Abnormality Patterns of B-Lineage Acute Lymphoblastic Leukemia in Adults in Comparison with Pediatric Cases

A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value

Serum 2-Hydroxyglutarate Level Is a Prognostic Marker in Acute Myeloid Leukemia

Long-Term Outcome of Imatinib Treatment in Chronic Myeloid Leukemia (CML) Patients in Shanghai: An International Patient Assistance Programs (GIPAP) Analysis.

Cytogenetic and Molecular Features of 1331 Chinese Patients with Primary Acute Lymphoblastic Leukemia (ALL).

Activation of PI3K/Akt/mTOR Pathway in Diffuse Large B-Cell Lymphomas: Clinical Significance and Inhibitory Effect by Rituximab.

Front-Line Therapy with Arsenic Trioxide/All- Trans -Retinoic Acid Combination and Chemotherapy Improves Cure Rates in Newly Diagnosed Patients with Acute Promyelocytic Leukemia

PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor

Rituximab plus CHOP (R-CHOP) overcomes PRDM1 -associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma

Long-Term Follow-Up Confirms the Benefit of All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As2O3) as Front Line Therapy for Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Long Term Follow up of the Patients with Non-Hodgkin’s Lymphoma Treated with Rituximab in Combination with CHOP Regimen.

Study of Sequential Treatment of Newly Diagnosed De Novo AML Patients with DA and CAG Regimens as Remission Induction Therapy.

A 3-Year Follow-Up of All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As 2 O 3 ) as Front Line Therapy for Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Phase I Clinical Trial of Glivec in Combination with Tetra-Arsenic Tetra-Sulfide in the Treatment of CML Patients in Advanced Phase.

Cytogenetic Abnormalities Predict Disease Progression in Primary Myelodysplastic Syndrome: A Multicentric Study in 508 Chinese Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only